Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Aerovate Therapeutics Inc.
Headquarters: Boston, MA, United States of America
Website: https://www.aerovatetx.com
Year Founded: 2018
Status: Public
Industry Sector: HealthTechnology
CEO: Timothy P. Noyes, MBA
Number Of Employees: 51
Enterprise Value: $474,120,787
PE Ratio: -0.82
Exchange/Ticker 1: NASDAQ:AVTE
Exchange/Ticker 2: N/A
Latest Market Cap: $71,320,000
BioCentury | Nov 5, 2024
Deals
Novo to use Ascendis’ TransCon for once-monthly GLP-1R agonist
Deals report: AbbVie-EvolveImmune, Genmab-Revitope and GSK-Chimagen partner for T cell engagers
BioCentury | Nov 1, 2024
Finance
How Fairmount’s Paragon incubator steered two more companies to NASDAQ
In BioCentury’s Public Equity Report: Paragon-backed Jade and Crescent each reverse-merging with public companies, raising combined $500M
BioCentury | Jul 9, 2024
Finance
2Q24 Wrap: Trickle down recovery?
Biopharmas above $5B in market cap are up, but everyone else languishes
BioCentury | Jun 19, 2024
Product Development
Clinical Report: Zentalis hold resurfaces WEE1 safety concerns
Plus data from BioNTech, MediLink, Nurix, Aerovate and more
BioCentury | Apr 26, 2023
Politics, Policy & Law
Industry asks CMS to drop cost-plus approach to IRA
Other stakeholders comment on rewarding RWE, criteria for orphan exemption, alternatives to QALYs, and more
BioCentury | Jul 1, 2021
Finance
June 30 Quick Takes: Beam looks to complement Apellis; plus Intellia, Aerovate, Hutchmed, Spero-Pfizer and more
Beam Therapeutics Inc. (NASDAQ:BEAM) unveiled a five-year partnership with Apellis Pharmaceuticals Inc. (NASDAQ:APLS) to collaborate on up to six research programs against complement system targets,
BioCentury | Aug 13, 2020
Emerging Company Profile
RA-incubated Aerovate to deploy $72.6M series A for inhaled imatinib for PAH
Powder aerosol formulations designed to avoid systemic effects that tripped up Novartis’ oral version
Items per page:
1 - 7 of 7